[
Management change
Thyroid cancer
Tyrosine kinase inhibitor
[131I]
[18F]FDG
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
22 Dec 2023
22 Dec 2023
Historique:
received:
27
09
2023
accepted:
04
12
2023
medline:
22
12
2023
pubmed:
22
12
2023
entrez:
22
12
2023
Statut:
aheadofprint
Résumé
In patients with iodine-negative thyroid cancer (TC), current guidelines endorse an [ 42 consecutive patients with negative findings on [ We observed no alterations of the treatment plan in 9/42 (21.4%) subjects (active surveillance in 9/9 [100%]). Oncological management was changed in the remaining 33/42 (78.6%; systemic treatment in 9/33 [27.3%] and non-systemic treatment in 24/33 [72.7%]). Among patients receiving non-systemic therapy, the following changes were noted: surgery in 20/24 (83.3%) and radiation therapy in 4/24 (16.7%). In the systemic group, tyrosine kinase inhibitor (TKI) was prescribed in 8/9 (88.9%), while radioiodine therapy based on a TKI-mediated redifferentiation approach was conducted in 1/9 (11.1%). In 26 subjects with available follow-up, rate of CD was 22/26 (84.6%) and among those, 15/22 (68.1%) had experienced previous management changes based on PET/CT findings. In subjects with iodine-negative TC, [
Sections du résumé
BACKGROUND
BACKGROUND
In patients with iodine-negative thyroid cancer (TC), current guidelines endorse an [
METHODS
METHODS
42 consecutive patients with negative findings on [
RESULTS
RESULTS
We observed no alterations of the treatment plan in 9/42 (21.4%) subjects (active surveillance in 9/9 [100%]). Oncological management was changed in the remaining 33/42 (78.6%; systemic treatment in 9/33 [27.3%] and non-systemic treatment in 24/33 [72.7%]). Among patients receiving non-systemic therapy, the following changes were noted: surgery in 20/24 (83.3%) and radiation therapy in 4/24 (16.7%). In the systemic group, tyrosine kinase inhibitor (TKI) was prescribed in 8/9 (88.9%), while radioiodine therapy based on a TKI-mediated redifferentiation approach was conducted in 1/9 (11.1%). In 26 subjects with available follow-up, rate of CD was 22/26 (84.6%) and among those, 15/22 (68.1%) had experienced previous management changes based on PET/CT findings.
CONCLUSIONS
CONCLUSIONS
In subjects with iodine-negative TC, [
Identifiants
pubmed: 38133766
doi: 10.1007/s12020-023-03645-8
pii: 10.1007/s12020-023-03645-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 453989101
Organisme : Deutsche Forschungsgemeinschaft
ID : 453989101
Organisme : Deutsche Forschungsgemeinschaft
ID : 453989101
Organisme : Japan Society for the Promotion of Science
ID : 22H03027
Organisme : Okayama University of Science
ID : RECTOR Program
Informations de copyright
© 2023. The Author(s).
Références
B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1), 1–133 (2016)
doi: 10.1089/thy.2015.0020
pubmed: 26462967
pmcid: 4739132
G. Dai, O. Levy, N. Carrasco, Cloning and characterization of the thyroid iodide transporter. Nature 379(6564), 458–460 (1996)
doi: 10.1038/379458a0
pubmed: 8559252
J.K. Hoang, B.F.T. Branstetter, A.R. Gafton, W.K. Lee, C.M. Glastonbury, Imaging of thyroid carcinoma with CT and MRI: approaches to common scenarios. Cancer Imaging 13(1), 128–139 (2013)
doi: 10.1102/1470-7330.2013.0013
pubmed: 23545125
pmcid: 3613791
H. Palmedo, J. Bucerius, A. Joe, H. Strunk, N. Hortling, S. Meyka et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47(4), 616–624 (2006)
pubmed: 16595495
H. Wang, H. Dai, Q. Li, G. Shen, L. Shi, R. Tian, Investigating (18)F-FDG PET/CT parameters as prognostic markers for differentiated thyroid cancer: a systematic review. Front Oncol 11, 648658 (2021)
doi: 10.3389/fonc.2021.648658
pubmed: 34055616
pmcid: 8158293
M. Liu, L. Cheng, Y. Jin, M. Ruan, S. Sheng, L. Chen, Predicting (131)I-avidity of metastases from differentiated thyroid cancer using (18)F-FDG PET/CT in postoperative patients with elevated thyroglobulin. Sci Rep 8(1), 4352 (2018)
doi: 10.1038/s41598-018-22656-4
pubmed: 29531251
pmcid: 5847528
R.A. Werner, C. Sayehli, H. Hanscheid, T. Higuchi, S.E. Serfling, M. Fassnacht et al. Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma. Eur J Nucl Med Mol Imaging 50(6), 1833–1834 (2023)
doi: 10.1007/s00259-022-06061-8
pubmed: 36522435
S.E. Serfling, P.E. Hartrampf, Y. Zhi, T. Higuchi, A. Kosmala, J. Serfling et al. Somatostatin receptor-directed PET/CT for therapeutic decision-making and disease control in patients affected with small cell lung cancer. Clin Nucl Med 48(4), 309–314 (2023)
doi: 10.1097/RLU.0000000000004591
pubmed: 36754127
pmcid: 9988212
S.E. Serfling, Y. Zhi, F. Megerle, M. Fassnacht, A.K. Buck, C. Lapa et al. Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma. Endocrine 78(1), 169–176 (2022)
doi: 10.1007/s12020-022-03116-6
pubmed: 35751778
pmcid: 9474330
T. Fullmer, M.E. Cabanillas, M. Zafereo, Novel therapeutics in radioactive iodine-resistant thyroid cancer. Front Endocrinol 12, 720723 (2021)
doi: 10.3389/fendo.2021.720723
M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7), 621–630 (2015)
doi: 10.1056/NEJMoa1406470
pubmed: 25671254
K.C. Bible, V.J. Suman, J.R. Molina, R.C. Smallridge, W.J. Maples, M.E. Menefee et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11(10), 962–972 (2010)
doi: 10.1016/S1470-2045(10)70203-5
pubmed: 20851682
pmcid: 3107731
M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940), 319–328 (2014)
doi: 10.1016/S0140-6736(14)60421-9
pubmed: 24768112
pmcid: 4366116
L.L. Covell, A.K. Ganti, Treatment of advanced thyroid cancer: role of molecularly targeted therapies. Target Oncol 10(3), 311–324 (2015)
doi: 10.1007/s11523-014-0331-z
pubmed: 26335853
L. Lamartina, N. Anizan, C. Dupuy, S. Leboulleux, M. Schlumberger, Redifferentiation-facilitated radioiodine therapy in thyroid cancer. Endocr Relat Cancer 28(10), T179–T191 (2021)
doi: 10.1530/ERC-21-0024
pubmed: 33690158
L. Groussin, L. Bessiene, J. Arrondeau, S. Garinet, B. Cochand-Priollet, A. Lupo et al. Letter to the Editor: selpercatinib-enhanced radioiodine uptake in RET-rearranged thyroid cancer. Thyroid 31(10), 1603–1604 (2021)
pubmed: 34405703
Z.L. Qiu, C.T. Shen, Z.K. Sun, H.J. Song, G.Q. Zhang, Q.Y. Luo, Lung metastases from papillary thyroid cancer with persistently negative thyroglobulin and elevated thyroglobulin antibody levels during radioactive iodine treatment and follow-up: long-term outcomes and prognostic indicators. Front Endocrinol 10, 903 (2019)
doi: 10.3389/fendo.2019.00903
S. Samnick, E. Al-Momani, J.S. Schmid, A. Mottok, A.K. Buck, C. Lapa, Initial clinical investigation of [
doi: 10.1097/RLU.0000000000001977
pubmed: 29356744
M. Dittmann, J.M. Gonzalez Carvalho, K. Rahbar, M. Schafers, M. Claesener, B. Riemann et al. Incremental diagnostic value of [(18)F]tetrafluoroborate PET-CT compared to [(131)I]iodine scintigraphy in recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 47(11), 2639–2646 (2020)
doi: 10.1007/s00259-020-04727-9
pubmed: 32248325
pmcid: 7515952
L.H. de Vries, L. Lodewijk, A. Braat, G.C. Krijger, G.D. Valk, M. Lam et al. 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with (177)Lu-PSMA-617. EJNMMI Res. 10(1), 18 (2020)